Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.70 |
| ▸ | RAB9A | P51151 | 7/20 | 0.70 |
| ▸ | MAPT | P10636 | 7/20 | 0.70 |
| ▸ | HTT | P42858 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.70 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.69 |
| ▸ | NPC1 | O15118 | 7/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | GAA | P10253 | 3/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.67 |
| ▸ | PTGES | O14684 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | VCP | P55072 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.65 |
| ▸ | AR | P10275 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12297207 | 0.91 | RAB9A (0.68) | MEN1KMT2ARAB9AMAPTHTT | |
| SCHEMBL18769586 | 0.88 | MEN1 (0.79) | MEN1KMT2ARAB9AMAPTHTT | |
| SCHEMBL12298108 | 0.86 | MEN1 (0.78) | MEN1KMT2ARAB9AMAPTHTT | |
| SCHEMBL12298082 | 0.86 | CSNK2A1 (0.67) | MEN1KMT2ARAB9AMAPTHTT | |
| SCHEMBL837836 | 0.86 | CSNK2A1 (0.67) | MEN1KMT2ARAB9AMAPTCSNK2A1 | |
| SCHEMBL12298171 | 0.86 | CYP1A2 (0.68) | MEN1KMT2ARAB9AMAPTCSNK2A1 | |
| SCHEMBL24467445 | 0.85 | MEN1 (0.71) | MEN1KMT2ARAB9AMAPTHTT | |
| SCHEMBL12297180 | 0.85 | CFTR (0.73) | MEN1KMT2ARAB9AMAPTCSNK2A1 | |
| SCHEMBL25959092 | 0.83 | RAB9A (0.68) | MEN1KMT2ARAB9AMAPTHTT | |
| SCHEMBL14458161 | 0.83 | CSNK2A1 (0.64) | MEN1KMT2ARAB9AMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017629-B2 | Compounds and uses thereof in modulating amyloid β | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017629-B2 | Compounds and uses thereof in modulating amyloid β | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100324032-A1 | COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA | NEUROGENETIC PHARMACEUTICALS, INC. | 2010-12-23 | — | — | US | disclosed |
| US-20100324032-A1 | COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA | NEUROGENETIC PHARMACEUTICALS, INC. | 2010-12-23 | — | — | US | disclosed |
| US-7781442-B2 | Compounds and uses thereof in modulating amyloid beta | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781442-B2 | Compounds and uses thereof in modulating amyloid beta | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20070260058-A1 | Compounds and Uses Thereof in Modulating Amyloid Beta | TORREYPINES THERAPEUTICS INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070260058-A1 | Compounds and Uses Thereof in Modulating Amyloid Beta | TORREYPINES THERAPEUTICS INC. | 2007-11-08 | — | — | US | disclosed |
| US-7244739-B2 | Compounds and uses thereof in modulating amyloid beta | TORREYPINES THERAPEUTICS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244739-B2 | Compounds and uses thereof in modulating amyloid beta | TORREYPINES THERAPEUTICS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324032-A1 | COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA | APP, BACE1, BACE2 | MEN1 2959/4885KMT2A 3770/4885RAB9A 2158/4885 |
| US-20070260058-A1 | Compounds and Uses Thereof in Modulating Amyloid Beta | APP, BACE1, BACE2 | MEN1 2959/4885KMT2A 3770/4885RAB9A 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.